Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function

Journal of the American Society of Nephrology

Volumn 17, Issue 9, 2006, Pages 2622-2632

  Scholten, Eduard M ^a   Rowshani, Ajda T ^b   Cremers, Serge ^a   Bemelman, Frederike J ^b   Eikmans, Michael ^a   Van Kan, Erik ^b   Mallat, Marko J ^a   Florquin, Sandrine ^b   Surachno, Janto ^b   Ten Berge, Ineke J ^b   Bajema, Ingeborg M ^a   De Fijter, Johan W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CELL INFILTRATION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RELIABILITY;

EID: 33748068114     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2006030227     Document Type: Article

References (54)

1. Paul LC: Chronic allograft nephropathy: An update. Kidney Int 56: 783-793, 1999
2. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB: Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346: 580-590, 2002
3. Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE: Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69: 834-841, 2000
4. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3: 178-185, 2003
5. Vincenti F: A decade of progress in kidney transplantation. Transplantation 77[Suppl]: S52-S61, 2004
6. Margreiter R: Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: A randomised multicentre study. Lancet 359: 741-746, 2002
7. Scott LJ, McKeage K, Keam SJ, Plosker GL: Tacrolimus: A further update of its use in the management of organ transplantation. Drugs 63: 1247-1297, 2003
8. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 78: 242-249, 2004
9. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, Trpkov K, Solez K, Jeffery J: Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 9: 2129-2134, 1998
10. Shishido S, Asanuma H, Nakai H, Mori Y, Satoh H, Kamimaki I, Hataya H, Ikeda M, Honda M, Hasegawa A: The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 14: 1046-1052, 2003
11. Moreso F, Lopez M, Vallejos A, Giordani C, Riera L, Fulladosa X, Hueso M, Alsina J, Grinyo JM, Seron D: Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant 1: 82-88, 2001
12. Shapiro R, Randhawa P, Jordan ML, Scantlebury VP, Vivas C, Jain A, Corry RJ, McCauley J, Johnston J, Donaldson J, Gray EA, Dvorchik I, Hakala TR, Fung JJ, Starzl TE: An analysis of early renal transplant protocol biopsies: The high incidence of subclinical tubulitis. Am J Transplant 1: 47-50, 2001
13. Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 66: 1736-1740,1998
14. Cosio FG, Grande JP, Larson TS, Gloor JM, Velosa JA, Textor SC, Griffin MD, Stegall MD: Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 5: 1130-1136, 2005
15. Grimm PC, Nickerson P, Gough J, McKenna R, Stern E, Jeffery J, Rush DN: Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 14: 1662-1668, 2003
16. Diaz Encarnacion MM, Griffin MD, Slezak JM, Bergstralh EJ, Stegall MD, Velosa JA, Grande JP: Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant 4: 248-256, 2004
17. Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, de Fijter JW: AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67: 2440-2447, 2005
18. Cremers SC, Scholten EM, Schoemaker RC, Lentjes EG, Vermeij P, Paul LC, den Hartigh J, de Fijter JW: A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 18: 1201-1208, 2003
19. Rowshani AT, Scholten EM, Bemelman F, Eikmans M, Idu M, van Groningen MC, Surachno JS, Mallat MJ, Paul LC, de Fijter JW, Bajema IM, Ten Berge I, Florquin S: No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol 17: 305-312, 2006
20. Roos-van Groningen MC, Scholten EM, Lelieveld PM, Rowshani AT, Baelde HJ, Bajema IM, Florquin S, Bemelman FJ, de Heer E, de Fijter JW, Bruijn JA, Eikmans M: Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 17: 881-888, 2006
21. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD: Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 78: 557-565, 2004
22. Seron D, Moreso F, Ramon JM, Hueso M, Condom E, Fulladosa X, Bover J, Gil-Vernet S, Castelao AM, Alsina J, Grinyo JM: Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 69: 1849-1855, 2000
23. Nicholson ML, Bailey E, Williams S, Harris KP, Furness PN: Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 68: 236-241, 1999
24. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
25. Nankivell BJ, Gruenewald SM, Allen RD, Chapman JR: Predicting glomerular filtration rate after kidney transplantation. Transplantation 59: 1683-1689, 1995
26. van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23: 119-128, 2001
27. di Paolo S, Teutonico A, Stallone G, Infante B, Schena A, Grandaliano G, Battaglia M, Ditonno P, Schena PF: Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients. Nephrol Dial Transplant 19: 2107-2112, 2004
28. Bakker RC, Koop K, Sijpkens YW, Eikmans M, Bajema IM, de Heer E, Bruijn JA, Paul LC: Early interstitial accumulation of collagen type I discriminates chronic rejection from chronic cyclosporine nephrotoxicity. J Am Soc Nephrol 14: 2142-2149, 2003
29. Seron D, Carrera M, Grino JM, Castelao AM, Lopez-Costea MA, Riera L, Alsina J: Relationship between donor renal interstitial surface and post-transplant function. Nephrol Dial Transplant 8: 539-543, 1993
30. Nickerson P, Jeffery J, Gough J, McKenna R, Grimm P, Cheang M, Rush D: Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol 9: 482-487, 1998
31. Bains JC, Sandford RM, Brook NR, Hosgood SA, Lewis GR, Nicholson ML: Comparison of renal allograft fibrosis after transplantation from heart-beating and non-heart-beating donors. Br J Surg 92: 113-118, 2005
32. Primmett DR, Levine M, Kovarik JM, Mueller EA, Keown PA: Cyclosporine monitoring in patients with renal transplants: Two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther Drug Monit 20: 276-283, 1998
33. Jorgensen K, Povlsen J, Madsen S, Madsen M, Hansen H, Pedersen A, Heinsvig EM, Poulsen J: C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 17: 1487-1490, 2002
34. Wong KM, Shek CC, Chau KF, Li CS: Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 35: 660-666, 2000
35. Mahalati K, Belitsky P, West K, Kiberd B, Fraser A, Sketris I, Macdonald AS, McAlister V, Lawen J, Mahalati K, Belitsky P, Sketris I, West K, Panek R: Approaching the therapeutic window for cyclosporine in kidney transplantation: A prospective study. J Am Soc Nephrol 12: 828-833, 2001
36. Tada H, Satoh S, Iinuma M, Shimoda N, Murakami M, Hayase Y, Kato T, Suzuki T: Chronopharmacokinetics of tacrolimus in kidney transplant recipients: Occurrence of acute rejection. J Clin Pharmacol 43: 859-865, 2003
37. Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ, Chapman JR: Effect of histological damage on long-term kidney transplant outcome. Transplantation 71: 515-523, 2001
38. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y: Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 75: 434-447, 2004
39. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2: 157-166, 2002
40. Seron D, Moreso F, Fulladosa X, Hueso M, Carrera M, Grinyo JM: Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 61: 727-733, 2002
41. Veronese FV, Manfro RC, Roman FR, Edelweiss MI, Rush DN, Dancea S, Goldberg J, Goncalves LF: Reproducibility of the Banff classification in subclinical kidney transplant rejection. Clin Transplant 19: 518-521, 2005
42. Furness PN, Taub N: International variation in the interpretation of renal transplant biopsies: Report of the CERT-PAP Project. Kidney Int 60: 1998-2012, 2001
43. Koop K, Bakker RC, Eikmans M, Baelde HJ, de Heer E, Paul LC, Bruijn JA: Differentiation between chronic rejection and chronic cyclosporine toxicity by analysis of renal cortical mRNA. Kidney Int 66: 2038-2046, 2004
44. Kaplan B, Schold JD, Meier-Kriesche HU: Long-term graft survival with Neoral and tacrolimus: A paired kidney analysis. J Am Soc Nephrol 14: 2980-2984, 2003
45. Baboolal K, Jones GA, Janezic A, Griffiths DR, Jurewicz WA: Molecular and structural consequences of early renal allograft injury. Kidney Int 61: 686-696, 2002
46. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD: Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 5: 2464-2472, 2005
47. Choi BS, Shin MJ, Shin SJ, Kim YS, Choi YJ, Kim YS, Moon IS, Kim SY, Koh YB, Bang BK, Yang CW: Clinical significance of an early protocol biopsy in living-donor renal transplantation: Ten-year experience at a single center. Am J Transplant 5: 1354-1360, 2005
48. Nickerson P, Jeffery J, Gough J, Grimm P, McKenna R, Birk P, Rush D: Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: A pilot study. J Am Soc Nephrol 10: 1801-1805, 1999
49. Meehan SM, Siegel CT, Aronson AJ, Bartosh SM, Thistlethwaite JR, Woodle ES, Haas M: The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies. J Am Soc Nephrol 10: 1806-1814, 1999
50. Sijpkens YW, Doxiadis II, Mallat MJ, de Fijter JW, Bruijn JA, Claas FH, Paul LC: Early versus late acute rejection episodes in renal transplantation. Transplantation 75: 204-208, 2003
51. Bakker RC, Hollander AA, Mallat MJ, Bruijn JA, Paul LC, de Fijter JW: Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 64: 1027-1034, 2003
52. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J: A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 78: 1653-1660, 2004
53. Gotti E, Perico N, Perna A, Gaspari F, Cattaneo D, Caruso R, Ferrari S, Stucchi N, Marchetti G, Abbate M, Remuzzi G: Renal transplantation: Can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. J Am Soc Nephrol 14: 755-766, 2003
54. Abramowicz D, Del Carmen RM, Vitko S, del Castillo D, Manas D, Lao M, Gafner N, Wijngaard P: Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 16: 2234-2240, 2005